A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Sponsor: BMS
Protocol Number: CA204-187
Start Date: 3/13/2017
Active, estimate end date – end of November 2020